Exhibit 99.1 Assertio Reports Fourth Quarter and Full Year 2023 Financial Results Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, IL. – March 11, 2024 – Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today report ...

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) and reminds investors of the March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 ...

If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ASRT. There is no cost or obligation to you. NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential ...

Shares of Assertio Holdings, Inc. (ASRT) have nosedived 64.5% in the past three months against the industry’s increase of 17.6%.In January 2024, the company’s chief executive officer (CEO), Dan Peisert, stepped down from his role with immediate effect.Assertio appointed Heather Mason, who had already served as the independent director of the company, as its new interim CEO.Mason, who has been with Assertio since 2019, also served as the chair of its Nominating and Corporate Governance Committee.Assertio’s c ...

MediaProduction Investment thesis Okay, admitted: This one's a troubled child. At one point in 2015, the common stock of Assertio Holdings, Inc. (NASDAQ:ASRT) traded at ~$130. Less than a year later it had lost more than half of that value, and with the exception of a spike in late 2016, Assertio's share price has known only one way: Down. In addition to the poor performance on the stock exchange, Assertio caught the eye of Beckers Hospital Review which placed Assertio on its list of 31 drug makers at h ...

LAKE FOREST, Ill., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that effective January 2, 2024, the Compensation Committee of the Company's Board of Directors granted two newly-hired employee a total of 16,498 restricted stock units ("RSUs") and 18,654 stock options ("options"). The RSUs ...

Assertio Holdings Inc. (NASDAQ:ASRT) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel - SVP & Chief Accounting Officer Paul Schwichtenberg - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti Scott Henry - ROTH MKM Partners Operator Good morning and welcome to the Assertio Holdings Inc. Third Quarter 2023 Financial Results Conference Call. All ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF INC ...

Assertio Holdings Inc. (NASDAQ:ASRT) Q2 2023 Earnings Call Transcript August 3, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Dan Peisert - President and CEO Paul Schwichtenberg - Senior Vice President and CFO Tom Riga - Outgoing CEO of Spectrum Pharmaceuticals Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hamed Khorsand - BWS Financial Inc Jim Sidoti - SIDOTI & Company Scott Henry - Roth Capital Operator Good morning, and welcome to the Assertio Holdings In ...